{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:00Z","timestamp":1793042760786,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"\n Importance<\/jats:title>\n Whether protein risk scores derived from a single plasma sample could be useful for risk assessment for atherosclerotic cardiovascular disease (ASCVD), in conjunction with clinical risk factors and polygenic risk scores, is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop protein risk scores for ASCVD risk prediction and compare them to clinical risk factors and polygenic risk scores in primary and secondary event populations.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The primary analysis was a retrospective study of primary events among 13\u202f540 individuals in Iceland (aged 40-75 years) with proteomics data and no history of major ASCVD events at recruitment (study duration, August 23, 2000 until October 26, 2006; follow-up through 2018). We also analyzed a secondary event population from a randomized, double-blind lipid-lowering clinical trial (2013-2016), consisting of individuals with stable ASCVD receiving statin therapy and for whom proteomic data were available for 6791 individuals.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Protein risk scores (based on 4963 plasma protein levels and developed in a training set in the primary event population); polygenic risk scores for coronary artery disease and stroke; and clinical risk factors that included age, sex, statin use, hypertension treatment, type 2 diabetes, body mass index, and smoking status at the time of plasma sampling.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes were composites of myocardial infarction, stroke, and coronary heart disease death or cardiovascular death. Performance was evaluated using Cox survival models and measures of discrimination and reclassification that accounted for the competing risk of non-ASCVD death.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the primary event population test set (4018 individuals [59.0% women]; 465 events; median follow-up, 15.8 years), the protein risk score had a hazard ratio (HR) of 1.93 per SD (95% CI, 1.75 to 2.13). Addition of protein risk score and polygenic risk scores significantly increased the C index when added to a clinical risk factor model (C index change, 0.022 [95% CI, 0.007 to 0.038]). Addition of the protein risk score alone to a clinical risk factor model also led to a significantly increased C index (difference, 0.014 [95% CI, 0.002 to 0.028]). Among White individuals in the secondary event population (6307 participants; 432 events; median follow-up, 2.2 years), the protein risk score had an HR of 1.62 per SD (95% CI, 1.48 to 1.79) and significantly increased C index when added to a clinical risk factor model (C index change, 0.026 [95% CI, 0.011 to 0.042]). The protein risk score was significantly associated with major adverse cardiovascular events among individuals of African and Asian ancestries in the secondary event population.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.13258","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:07:42Z","timestamp":1692702462000},"page":"725","source":"Crossref","is-referenced-by-count":134,"title":["Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events"],"prefix":"10.1001","volume":"330","author":[{"given":"Hannes","family":"Helgason","sequence":"first","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thjodbjorg","family":"Eiriksdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus O.","family":"Ulfarsson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun H.","family":"Lund","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna V.","family":"Ivarsdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grimur","family":"Hjorleifsson Eldjarn","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Einarsson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil","family":"Ferkingstad","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristjan H. S.","family":"Moore","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimon","family":"Honarpour","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Liu","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hucko","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Birger","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Zealand University Hospital, K\u00f8ge, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bundgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Arnar","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"},{"name":"Landspitali\u2014The National University Hospital of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Thorgeirsson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"},{"name":"Landspitali\u2014The National University Hospital of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00edsli","family":"Masson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur Th.","family":"Magnusson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jona","family":"Saemundsdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig","family":"Gretarsdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valgerdur","family":"Steinthorsdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmar","family":"Thorleifsson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Helgadottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sulem","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnur","family":"Thorsteinsdottir","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilma","family":"Holm","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gudbjartsson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Stefansson","sequence":"additional","affiliation":[{"name":"deCODE genetics\/Amgen, Inc, Reykjavik, Iceland"},{"name":"University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"joi230088r1","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"11","key":"joi230088r2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"issue":"25","key":"joi230088r3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"joi230088r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4181","article-title":"Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2.","volume":"344","author":"Collins","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"joi230088r5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"9750","key":"joi230088r6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(10)61267-6","article-title":"A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses.","volume":"376","author":"Ripatti","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"joi230088r7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jacc.2018.07.079","article-title":"Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention.","volume":"72","author":"Inouye","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"joi230088r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002546","article-title":"Cardiovascular disease: the rise of the genetic risk score.","volume":"15","author":"Knowles","year":"2018","journal-title":"PLoS Med"},{"issue":"7","key":"joi230088r9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/jama.2019.22241","article-title":"Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease.","volume":"323","author":"Elliott","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"joi230088r10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jama.2019.21782","article-title":"Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease.","volume":"323","author":"Mosley","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"joi230088r11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"joi230088r12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s42003-021-02289-6","article-title":"Predicting the probability of death using proteomics.","volume":"4","author":"Eiriksdottir","year":"2021","journal-title":"Commun Biol"},{"issue":"10","key":"joi230088r13","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.49","article-title":"Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents.","volume":"3","author":"Rohloff","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"joi230088r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability.","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"joi230088r15","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","article-title":"Plasma protein patterns as comprehensive indicators of health.","volume":"25","author":"Williams","year":"2019","journal-title":"Nat Med"},{"issue":"14","key":"joi230088r16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008108","article-title":"Protein biomarkers of cardiovascular disease and mortality in the community.","volume":"7","author":"Ho","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"joi230088r17","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2016.5951","article-title":"Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease.","volume":"315","author":"Ganz","year":"2016","journal-title":"JAMA"},{"issue":"41","key":"joi230088r18","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1093\/eurheartj\/ehaa648","article-title":"Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention.","volume":"41","author":"Hoogeveen","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"joi230088r19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/eurheartj\/ehac055","article-title":"Targeted proteomics improves cardiovascular risk prediction in secondary prevention.","volume":"43","author":"Nurmohamed","year":"2022","journal-title":"Eur Heart J"},{"issue":"639","key":"joi230088r20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj9625","article-title":"A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.","volume":"14","author":"Williams","year":"2022","journal-title":"Sci Transl Med"},{"issue":"12","key":"joi230088r21","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","article-title":"Large-scale integration of the plasma proteome with genetics and disease.","volume":"53","author":"Ferkingstad","year":"2021","journal-title":"Nat Genet"},{"key":"joi230088r22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"issue":"18","key":"joi230088r23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"joi230088r24","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"joi230088r25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/rssb.1972.34.issue-2","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"4","key":"joi230088r26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the Cox model.","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat Med"},{"issue":"5","key":"joi230088r27","doi-asserted-by":"crossref","first-page":"E727","DOI":"10.1073\/pnas.1612113114","article-title":"Selection against variants in the genome associated with educational attainment.","volume":"114","author":"Kong","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"joi230088r28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","article-title":"Concordance for prognostic models with competing risks.","volume":"15","author":"Wolbers","year":"2014","journal-title":"Biostatistics"},{"issue":"25","key":"joi230088r29","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology.","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"joi230088r30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"issue":"1","key":"joi230088r31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"joi230088r32","first-page":"38","article-title":"Can machine learning bring cardiovascular risk assessment to the next level? a methodological study using FOURIER trial data.","volume":"3","author":"Rousset","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"joi230088r34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities.","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"issue":"1","key":"joi230088r35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003092","article-title":"Transethnic transferability of a genome-wide polygenic score for coronary artery disease.","volume":"14","author":"Fahed","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"joi230088r36","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis.","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"joi230088r33","volume-title":"XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. KDD \u201916. Association for Computing Machinery; 2016:785-794","author":"Chen"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2808522\/jama_helgason_2023_oi_230088_1692287105.47489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:07:49Z","timestamp":1692702469000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2808522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.13258","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}